Halo Collective Inc has announced they will not be pursuing the acquisition of PhytoCann Holdings SA citing market conditions.
“I have worked in the legal U.S. cannabis industry for nearly a decade and frankly have never seen market conditions as challenging as what we are experiencing today. In conjunction with the Board of Directors, I have therefore decided to focus on Halo’s core assets, including California and Oregon,” said Katie Field, Halo’s CEO and Director. “We are simplifying and strengthening in order to enhance shareholder value. Even under the best conditions, managing an international business out of our core product line presents complexities. We wish PhytoCann’s management all the best and look forward to their continued success.”
WEED Inc has acquired Hempirical Genetics LLC with a shares and cash deal. This will help WEED Inc expand its research and development of new products both pharma and non-pharma.
“Our teams in USA, Australia and Israel are excited that a pipeline of Original “Landrace” strains from the 1970s’ can now be moved into clinical trials and product development for the global market. WEED now has over 15 “PURE” original, pristine, F-1 grade cannabis strains today, including, Panama Red, Acapulco Gold, Red Bud Colombian & Santa Marta Gold,” said Glenn E. Martin, WEED, Inc.’s Chief Executive Officer. “Our newly acquired inventory includes over 30 CBD & CBG strains as WEED believes that multiple combinations of precise cannabinoid strains will create the entourage effect to achieve the medical outcome desired. Eventually, WEED plans to bring our unique desired strains to the Adult Use markets once the ‘Law of the Land’ brings back the Freedoms lost 70+ years ago.”
CuraLeaf Holdings Inc has launched Plant Precision, a collection of cannabis edibles and topical gel. The line aims to deliver customizable low dose THC and high doses of non-psychoactive cannabinoids like CBN, CBG, THCV, and CBD.
“With Plant Precision we wanted to create a simplified way people can incorporate cannabis into their daily health and wellness routines,” announced Matt Darin, CEO of Curaleaf. “These products empower people to explore cannabis beyond THC and CBD and offers more customizable solutions on how the plant can best serve a consumer’s personalized needs.”
Tilray Brands Inc revealed their new European medical cannabis education platform for healthcare professionals, patients, and caregivers. WeCare-MedicalCannabis is designed to be a comprehensive resource for personal wellness education. It is currently available in France, United Kingdom, Germany, and Portugal.
“As global pioneers in medical cannabis, we are aware of the lack of access to science-based, medical cannabis education. WeCare-MedicalCannabis was created to bridge that gap and help provide the needed resources to helping patients, caregivers, and healthcare professionals with the information they need to make informed decisions on medicinal cannabis,” said Sascha Mielcarek, Managing Director for Tilray Europe. “As cannabis legalization continues to expand across Europe, Tilray Medical is dedicated to help provide informed and trusted guidance for those interested in learning more about medical cannabis.”
Press release: https://tilray.gcs-web.com/news-releases/news-release-details/tilray-medical-launches-cannabis-education-platform-wecare
Braxia Scientific Corp appointed Daniel Herrera as Vice President of Research and Development. Their new Growth and Chief Information Officer is Jason Wolkove.
“Jason brings deep technology expertise and a strong track record of success with a passion for solving problems through innovative technology solutions. We look forward to his guidance as we implement our technology vision and focus on scaling up our clinical ketamine and psilocybin therapy programs, as well as clinical trials, to meet increasing demand for affordable access to innovative treatments for depression,” said Dr. Roger McIntyre, CEO of Braxia Scientific. “We are delighted to welcome Daniel, adding high caliber global pharmaceutical leadership to the Braxia management team. Daniel’s significant experience in global clinical development and the marketing of innovative medicines across several therapeutic areas, combined with his experience as a key leader in the development of multiple innovative therapeutics, are important skill sets that complement Braxia’s leading research team. His deep knowledge of the psychoactive segment and experience working with global regulatory agencies, including FDA and Health Canada among others, will be an invaluable contributor to our growth and the acceleration of our development pipeline.”
Press release: newswire.ca/news-releases/braxia-scientific-bolsters-leadership-with-strategic-hires-adds-chief-information-officer-and-global-pharmaceutical-industry-leader-as-vp-r-amp-d-and-growth-888633299.html
Green Scientific Labs Holdings Inc has launched a new proprietary laboratory information management system. The software provides new features and improved customization for clients.
“Successful cannabis laboratories must be able to keep up with continuously evolving regulations and requirements without sacrificing quality, consistency, or accuracy,” said Dr. Kristofer Marsh, Chief Scientific Officer of Green Scientific Labs. “Our new LIMS is faster, smarter, and perhaps most importantly, tailored specifically to our unique processes. Having full control of the technology that manages laboratory data allows us to continuously improve internal processes and create custom solutions for clients and employees.”
